| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Asal Pilehvari, Gretchen Kimmick, Wen You, Gloribel Bonilla, Roger Anderso. Disparities in receipt of 1- Breast cancer research : BCR. vol 26. issue 1. 2024-10-19. PMID:39425174. |
disparities in receipt of 1- this study used real-world observational data to compare profiles of patients receiving different first-line treatment for hormone receptor positive (er+), her2 negative, metastatic breast cancer (mbc): cdk4/6 inhibitors (cdk4/6i) in combination with endocrine therapy (et) versus et alone. |
2024-10-19 |
2024-10-21 |
Not clear |
| Tomasz Sirek, Agata Sirek, Marcin Opławski, Dariusz Boroń, Michał Chalcarz, Piotr Ossowski, Konrad Dziobek, Nikola Zmarzły, Damian Strojny, Beniamin Oskar Grabare. Expression profile of messenger and micro RNAs related to the histaminergic system in patients with five subtypes of breast cancer. Frontiers in oncology. vol 14. 2024-09-14. PMID:39267843. |
disparities in estrogen receptor (er), progesterone receptor, human epidermal growth factor receptor 2 (her2), and ki67 proliferation indices facilitate the categorization of breast cancer into four principal subtypes: luminal a, luminal b, her2-positive, and triple-negative breast cancer (tnbc). |
2024-09-14 |
2024-09-16 |
human |
| Gelan Ayana, Eonjin Lee, Se-Woon Cho. Vision transformers for breast cancer human epidermal growth factor receptor 2 (HER2) expression staging without immunohistochemical (IHC) staining. The American journal of pathology. 2023-12-14. PMID:38096984. |
this work holds great importance, aiding her2 expression staging in breast cancer treatment while circumventing the costly and time-consuming ihc staining procedure, thereby addressing diagnostic disparities in low-resource settings and low-income countries. |
2023-12-14 |
2023-12-17 |
human |
| Tiago Biachi de Castria, Laura Tang, Marcello Moro Queiroz, Beatriz Mendes Awni, Viktoriya Paroder, Ali Shamseddine, Giovanni Mendonca Bariani, Deborah Mukherji, Charbel F Matar, Gustavo Dos Santos Fernandes, Ashwaq El-Olayan, Fouad Sabatin, Rawad Elias, Ranju Gupta, Yelena Y Janjigian, Ghassan K Abou-Alf. Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. Journal of gastrointestinal oncology. vol 12. issue 6. 2022-01-24. PMID:35070435. |
histopathological analysis presented with disparities regarding her2 and programmed death-ligand 1 (pd-l1) status in the primary and metastatic sites. |
2022-01-24 |
2023-08-13 |
Not clear |
| Anya Litvak, Bhavina Batukbhai, Stuart D Russell, Hua-Ling Tsai, Gary L Rosner, Stacie C Jeter, Deborah Armstrong, Leisha A Emens, John Fetting, Antonio C Wolff, Raquel Silhy, Vered Stearns, Roisin M Connoll. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer. vol 124. issue 9. 2019-09-10. PMID:29381193. |
human epidermal growth factor receptor 2 (her2)-targeted therapies are highly effective at preventing breast cancer recurrence but are associated with cardiotoxicity in some patients, and minimal data are available regarding racial disparities in the incidence of this toxicity. |
2019-09-10 |
2023-08-13 |
human |
| David J Press, Abiola Ibraheem, M Eileen Dolan, Kathleen H Goss, Suzanne Conzen, Dezheng Hu. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast cancer research and treatment. vol 168. issue 1. 2019-03-19. PMID:29181717. |
to examine racial/ethnic disparities in oncotype dx (odx) testing among patients with node-negative, estrogen receptor (er)-positive, human epidermal growth factor receptor 2 (her2)-negative breast cancers and possible racial/ethnic disparities in chemotherapy receipt following odx testing within recurrence score (rs) category (not done, low, intermediate, high), as well as chemotherapy receipt time trends within rs categories. |
2019-03-19 |
2023-08-13 |
human |
| Jianbin Li, Shusen Wang, Yongsheng Wang, Xiaojia Wang, Haibo Wang, Jifeng Feng, Qingyuan Zhang, Tao Sun, Quchang Ouyang, Yongmei Yin, Yinhua Liu, Cuizhi Geng, Min Yan, Zefei Jian. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China. The oncologist. vol 22. issue 11. 2018-07-09. PMID:28798274. |
disparities of trastuzumab use in resource-limited or resource-abundant regions and its survival benefit on her2 positive breast cancer: a real-world study from china. |
2018-07-09 |
2023-08-13 |
human |
| Andreana N Holowatyj, Julie J Ruterbusch, Manohar Ratnam, David H Gorski, Michele L Cot. HER2 status and disparities in luminal breast cancers. Cancer medicine. vol 5. issue 8. 2017-11-16. PMID:27250116. |
her2 status and disparities in luminal breast cancers. |
2017-11-16 |
2023-08-13 |
Not clear |
| Katherine Reeder-Hayes, Sharon Peacock Hinton, Ke Meng, Lisa A Carey, Stacie B Dusetzin. Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. vol 34. issue 17. 2017-06-30. PMID:27069085. |
the recent addition of her2 information to the seer-medicare database offers an opportunity to examine patterns of trastuzumab use and to evaluate possible disparities in receipt of trastuzumab. |
2017-06-30 |
2023-08-13 |
human |
| Lu Chen, Christopher I L. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. vol 24. issue 11. 2016-08-23. PMID:26464428. |
racial disparities in breast cancer diagnosis and treatment by hormone receptor and her2 status. |
2016-08-23 |
2023-08-13 |
Not clear |
| Huiyan Ma, Yani Lu, Kathleen E Malone, Polly A Marchbanks, Dennis M Deapen, Robert Spirtas, Ronald T Burkman, Brian L Strom, Jill A McDonald, Suzanne G Folger, Michael S Simon, Jane Sullivan-Halley, Michael F Press, Leslie Bernstei. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC cancer. vol 13. 2014-01-10. PMID:23642215. |
however, few studies have investigated the black-white disparity in mortality risk stratified by breast cancer subtype, defined by estrogen receptor (er), progesterone receptor (pr) and human epidermal growth factor receptor 2 (her2) status. |
2014-01-10 |
2023-08-12 |
human |